These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1281 related articles for article (PubMed ID: 33951220)

  • 1. Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection.
    Candoni A; Pizzano U; Fabris M; Curcio F; Fanin R
    Hematol Oncol; 2021 Aug; 39(3):428-431. PubMed ID: 33951220
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.
    Bird PW; Badhwar V; Kennedy B; Ladani S; Tang JW
    J Med Virol; 2021 Jul; 93(7):4585-4591. PubMed ID: 33595119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.
    Marasco V; Carniti C; Guidetti A; Farina L; Magni M; Miceli R; Calabretta L; Verderio P; Ljevar S; Serpenti F; Morelli D; Apolone G; Ippolito G; Agrati C; Corradini P
    Br J Haematol; 2022 Feb; 196(3):548-558. PubMed ID: 34649298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroconversion against SARS-CoV-2 occurred after the recovery in patients with COVID-19.
    Yamamoto S; Saito M; Nagai E; Toriuchi K; Nagai H; Yotsuyanagi H; Nakagama Y; Kido Y; Adachi E
    J Med Virol; 2021 Feb; 93(2):692-694. PubMed ID: 32897566
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody responses against SARS-CoV-2 in COVID-19 patients.
    Liu A; Li Y; Peng J; Huang Y; Xu D
    J Med Virol; 2021 Jan; 93(1):144-148. PubMed ID: 32603501
    [No Abstract]   [Full Text] [Related]  

  • 7. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
    Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
    Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed virus-specific antibody responses associate with COVID-19 mortality.
    Wang F; Yao Y; Hou H; Wu S; Guo C; Zhou H; Liu Z; Sun Z
    Allergy; 2021 Feb; 76(2):574-577. PubMed ID: 32754908
    [No Abstract]   [Full Text] [Related]  

  • 9. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric evaluation of clinical specificity and sensitivity of SARS-CoV-2 IgG and IgM serology assays.
    Bohn MK; Hall A; Wilson S; Taher J; Sepiashvili L; Adeli K
    Clin Chem Lab Med; 2021 May; 59(6):e235-e237. PubMed ID: 33577725
    [No Abstract]   [Full Text] [Related]  

  • 11. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
    Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
    JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
    Passamonti F; Romano A; Salvini M; Merli F; Porta MGD; Bruna R; Coviello E; Romano I; Cairoli R; Lemoli R; Farina F; Venditti A; Busca A; Ladetto M; Massaia M; Pinto A; Arcaini L; Tafuri A; Marchesi F; Fracchiolla N; Bocchia M; Armiento D; Candoni A; Krampera M; Luppi M; Cardinali V; Galimberti S; Cattaneo C; La Barbera EO; Mina R; Lanza F; Visani G; Musto P; Petrucci L; Zaja F; Grossi PA; Bertù L; Pagano L; Corradini P;
    Br J Haematol; 2021 Nov; 195(3):371-377. PubMed ID: 34272724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.
    Attolico I; Tarantini F; Carluccio P; Schifone CP; Delia M; Gagliardi VP; Perrone T; Gaudio F; Longo C; Giordano A; Sgherza N; Curci P; Rizzi R; Ricco A; Russo Rossi A; Albano F; Larocca AMV; Vimercati L; Tafuri S; Musto P
    Br J Haematol; 2022 Feb; 196(4):928-931. PubMed ID: 34664267
    [No Abstract]   [Full Text] [Related]  

  • 14. Serological evaluation of patients with coronavirus disease-2019 in Daegu, South Korea.
    Park S; Chang SH; Lee JH; Lee JH; Ham JY; Kim YK; Kim SG; Ryoo NH
    PLoS One; 2022; 17(1):e0262820. PubMed ID: 35051239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients.
    Efrati S; Catalogna M; Abu Hamed R; Hadanny A; Bar-Chaim A; Benveniste-Levkovitz P; Strugo R; Levtzion-Korach O
    Sci Rep; 2021 Jul; 11(1):13780. PubMed ID: 34215811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay.
    Pieri M; Nuccetelli M; Nicolai E; Sarubbi S; Grelli S; Bernardini S
    J Med Virol; 2021 Apr; 93(4):2523-2528. PubMed ID: 33463719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
    Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
    J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
    Al-Mughales JA; Al-Mughales TJ; Saadah OI
    Front Immunol; 2021; 12():705441. PubMed ID: 34539635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.